Balancing the cost, access to and risk management of CAR-T cell therapies is critical, according to a panel of experts who presented at the annual meeting of the Academy of Managed Care Pharmacy in Houston.

Survival rates have improved as treatment advances have multiplied, including CAR-T and bispecific antibodies.

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the U.S. market, launching in May 2024.

A small, multi-country analysis of women of child-rearing age has found that these patients experience limits on activities of daily living, challenges with the healthcare system and a high overall financial burden.

By 2023, approximately 1 in 5 patients with non-small cell lung cancer or metastatic colorectal cancer were treated with a bevacizumab biosimilar.

Digital solutions are needed in healthcare now so that more patients can get the access that they need, according to Vin Gupta, M.D., MPA, former chief medical officer of Amazon Pharmacy and a leading health policy expert.

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control group.

Participants in the FORWARD-53 trial had clinically significant improvements in time-to-rise, among other metrics.

The results of a new study in mice show that early exposure to certain bacteria and fungus can give the immune system a boost and reduce the risk of type 1 diabetes.

A BLA has been filed for bentracimab and, if approved, has the potential to be the first therapy to reverse the effects of Brilinta for patients who have bleeding events or who need urgent surgery.

Cardiac arrests in contemporary film are largely inaccurate when it comes to survival rate and etiology, according to a poster presented today at the American College of Cardiology conference held March 29 to 31 in Chicago.

The annual meeting of the Academy of Managed Care Pharmacy will take place in Houston from March 31 - April 3 at the George R. Brown Convention Center.

Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with chronic kidney disease as those without it, and there are signals that it has benefits for renal function.

In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension.

Clopidogrel monotherapy may be an alternative to aspirin for prevention of cardiac events in high-risk patients after percutaneous coronary intervention, according to a new study presented at ACC 2025.

Compared with other studies, the differences in outcomes between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) narrowed in the FAME 3 five-year follow-up study, but there were fewer myocardial infarctions and repeat revascularizations in the PCI group.

The rate of cardiovascular death, nonfatal heart attack, or nonfatal stroke was 30% lower among patients receiving nurse-led follow-up care after acute coronary syndrome.

Here’s what you missed this week on Managed Healthcare Executive.

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and all-cause death.

The largest randomized study of fluid intake restrictions showed no benefit from the restrictions, according to its senior author.

Researchers report yet another positive finding for GLP-1s. The participants in this trial had lower BMIs than the participants in the many other trials that have shown the benefits of the GLP-1s.

Novo Nordisk has submitted a supplemental application to the FDA for Rybelsus 14 mg to lower cardiovascular risk in adults with type 2 diabetes. A regulatory decision is anticipated in 2025.

The results are one of 10 from the FINEARTS-HF that are scheduled for presentation at the